---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-038446"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2026-08-14T20:30:49+00:00"
generated_at: "2026-08-14T20:36:19.933549+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma shareholders approve reverse stock split and incentive plan amendments

## Summary
- Approved reverse stock split (1-for-10 to 1-for-30) and cut authorized common to 25M, preferred to 1.5M.
- Elected directors Breen, Casamento, Kramer, Mun-Gavin; votes ranged 6.7M-8.1M for.
- Ratified Weinberg & Company as independent auditor for FY2026 (22.7M for).
- Approved non-binding executive compensation (6.1M for) and 2022 Plan amendments adding 3.5M shares and evergreen provision.

## SEC filing metadata
- accession: 0001493152-26-038446
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2026-08-14T20:30:49+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/0001493152-26-038446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-038446
- JSON: https://secwatch.observer/filing/0001493152-26-038446.json
- Plain text: https://secwatch.observer/filing/0001493152-26-038446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.